Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study
This sub-analysis of the ReTrITA cohort demonstrates that regorafenib dose escalation is achievable in real-world settings, resulting in notable improvements in progression-free survival and enhanced tolerability, while not adversely affecting overall survival. These results support and improve the findings of the ReDOS study, showing that dosage escalation is possible and helpful in a diverse, unselected group of people, which is what is performed in routine oncology treatment. The findings are consistent with both randomised and observational studies, endorsing individualised dosing as a practical strategy in refractory mCRC.
Authors
- Emanuela Dell’Aquila (ORCID: https://orcid.org/0000-0002-7258-1364)
- Manuela Dettori
- Maria Cristina Morelli (ORCID: https://orcid.org/0000-0002-9742-1981)
- Michele A. Basso (ORCID: https://orcid.org/0000-0001-8644-2966)
- Maria Alessandra Calegari (ORCID: https://orcid.org/0000-0001-6856-2593)
- Ina Valeria Zurlo (ORCID: https://orcid.org/0000-0002-8876-4691)
- Adele Artemi
- Annunziato Anghelone (ORCID: https://orcid.org/0009-0003-2647-2110)
- Federica Mazzuca (ORCID: https://orcid.org/0000-0002-6580-286X)
- Emanuela Lucci‐Cordisco (ORCID: https://orcid.org/0000-0002-6279-7604)
- Alessandro Bittoni (ORCID: https://orcid.org/0000-0002-4056-0067)
- Marta Ribelli
- Antonella Cosimati (ORCID: https://orcid.org/0000-0002-2636-3198)
- Marta Schirripa (ORCID: https://orcid.org/0000-0001-8316-4411)
- Jessica Lucchetti (ORCID: https://orcid.org/0000-0002-0262-535X)
- Maria Grazia Morandi
- Domenico Corsi (ORCID: https://orcid.org/0000-0002-5017-6704)
- Donatello Gemma
- Federica Zoratto (ORCID: https://orcid.org/0000-0001-8387-1968)
- Francesco Schietroma (ORCID: https://orcid.org/0009-0009-9669-8602)
- Carlo Signorelli (ORCID: https://orcid.org/0000-0001-9710-4962)
- Alessandro Minelli (ORCID: https://orcid.org/0000-0003-3387-1489)
- Giulia Arrivi (ORCID: https://orcid.org/0000-0003-0541-415X)
- Lorenzo Angotti (ORCID: https://orcid.org/0009-0002-8378-2943)
- Chiara Gallio (ORCID: https://orcid.org/0009-0003-7380-1255)
- Fiorenza Santamaria (ORCID: https://orcid.org/0000-0002-1214-9342)
- Alessandra Emiliani (ORCID: https://orcid.org/0000-0001-8193-7599)
- Rosa Saltarelli
- Alessandro Passardi (ORCID: https://orcid.org/0000-0002-7099-240X)
- Mario Giovanni Chilelli
- Emanuela Di Giacomo (ORCID: https://orcid.org/0009-0007-3006-3554)
Institutions
- University of Rome Tor Vergata (IT)
- Policlinico Umberto I (IT)
- Agostino Gemelli University Polyclinic (IT)
- Accademia di Belle Arti di Frosinone (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Azienda Sanitaria Locale Viterbo (IT)
- Ospedale San Paolo (IT)
- Azienda Ospedaliera Sant'Andrea (IT)
- National Cancer Institute (MY)
- Ospedale Santa Maria Goretti (IT)
- Campus Bio Medico University Hospital (IT)
- Ospedale Vito Fazzi (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-14
- DOI
- https://doi.org/10.3390/cancers17203316
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05